Assertio Holdings, Inc. (ASRT)

Assertio Holdings, Inc. (ASRT) Healthcare & Pipeline Overview

Assertio Holdings, Inc. develops and commercializes specialty pharmaceutical products, primarily in neurology, hospital, and pain management. With a focus on revitalizing established brands, Assertio navigates a competitive landscape against larger pharmaceutical companies and generic drug manufacturers, maintaining a presence through targeted therapies and strategic acquisitions.

What Is the Investment Thesis for ASRT?

Assertio Holdings, Inc. presents a mixed investment thesis. The company's focus on acquiring and revitalizing mature pharmaceutical products offers potential for revenue generation and margin expansion. The gross margin of 70.2% indicates strong pricing power and efficient cost management. However, the negative profit margin of -24.9% raises concerns about overall profitability and operational efficiency. Key growth catalysts include successful integration of acquired products and expansion into new therapeutic areas. Risks include competition from generic alternatives, regulatory challenges, and reliance on a limited number of key products. Monitoring the company's ability to improve profitability and manage its debt will be crucial for assessing its long-term investment viability. The company's beta of 0.79 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

ASRT Key Highlights

• Market capitalization of $151.86M reflects the company's current valuation in the specialty pharmaceutical market.
• Gross margin of 70.2% indicates strong pricing power and efficient cost management in its product portfolio.
• Negative profit margin of -24.9% highlights challenges in achieving overall profitability despite high gross margins.
• Beta of 0.79 suggests lower volatility compared to the broader market, potentially appealing to risk-averse investors.
• No dividend yield reflects a focus on reinvesting earnings for growth rather than returning capital to shareholders.

Who Are ASRT's Competitors?

ASRT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ASRT's Key Strengths?

• Established portfolio of specialty pharmaceutical products.
• High gross margin indicates strong pricing power.
• Experienced management team with expertise in commercial operations.
• Focus on niche markets with limited competition.

What Are ASRT's Weaknesses?

• Negative profit margin raises concerns about overall profitability.
• Reliance on a limited number of key products.
• Exposure to generic competition and patent expirations.
• Small market capitalization limits access to capital.

What Could Drive ASRT Stock Higher?

• Potential FDA approval for new formulations or indications of existing products.
• Integration of recently acquired pharmaceutical assets to drive revenue growth.
• Strategic partnerships to expand market reach and product development capabilities.

What Are the Key Risks for ASRT?

• Financial-distress signal — its Altman Z-Score of -3.71 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-38.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Increased competition from generic alternatives and biosimilars.
• Regulatory challenges and changes in healthcare policies.
• Product liability claims and litigation risks.
• Dependence on key products for a significant portion of revenue.

What Are the Growth Opportunities for ASRT?

• Expansion into New Therapeutic Areas: Assertio can explore opportunities to expand its product portfolio into new therapeutic areas, such as dermatology or gastroenterology. These areas represent significant market opportunities with growing demand for specialized treatments. By acquiring or developing products in these areas, Assertio can diversify its revenue streams and reduce its reliance on existing products. The global dermatology market is projected to reach $36.6 billion by 2027, while the gastroenterology market is expected to reach $52.5 billion by 2028.
• Strategic Acquisitions: Assertio can pursue strategic acquisitions of complementary pharmaceutical products or companies to expand its market presence and product offerings. This approach allows the company to quickly add revenue-generating assets and leverage its existing commercial infrastructure. Identifying undervalued or underperforming assets with growth potential can create significant value for Assertio. The pharmaceutical M&A market remains active, with deal values expected to increase in the coming years.
• Geographic Expansion: Assertio can explore opportunities to expand its geographic reach beyond the United States. Entering new markets, such as Europe or Asia, can provide access to larger patient populations and increase revenue potential. This expansion requires careful consideration of regulatory requirements, market dynamics, and competitive landscapes. The global pharmaceutical market is increasingly driven by growth in emerging markets.
• Product Line Extensions: Assertio can focus on developing product line extensions for its existing medications. This involves creating new formulations, dosages, or delivery methods to enhance the therapeutic benefits and patient convenience. Product line extensions can extend the lifecycle of existing products and generate additional revenue streams. The pharmaceutical industry is constantly innovating to improve drug delivery and patient outcomes.
• Partnerships and Collaborations: Assertio can establish partnerships and collaborations with other pharmaceutical companies or research institutions to develop and commercialize new products. This approach allows the company to share the risks and costs of drug development while leveraging the expertise and resources of its partners. Collaborative efforts can accelerate the development process and increase the likelihood of successful product launches. The pharmaceutical industry relies heavily on collaborations to drive innovation and growth.

What Opportunities Does ASRT Have?

• Expansion into new therapeutic areas and geographic markets.
• Strategic acquisitions of complementary pharmaceutical products.
• Development of product line extensions and new formulations.
• Partnerships and collaborations with other pharmaceutical companies.

What Threats Does ASRT Face?

• Increasing competition from generic drug manufacturers.
• Regulatory challenges and changes in healthcare policies.
• Product liability claims and litigation risks.
• Economic downturns and reduced healthcare spending.

What Are ASRT's Competitive Advantages?

• Established brand recognition for key products like INDOCIN and CAMBIA.
• Specialized expertise in marketing and commercializing mature pharmaceutical products.
• Proprietary formulations and delivery methods for certain medications.
• Regulatory exclusivity and patent protection for select products.

What Does ASRT Do?

Assertio Holdings, Inc., established in 1995 and headquartered in Lake Forest, Illinois, operates as a specialty pharmaceutical company dedicated to providing medicines in the neurology, hospital, and pain and inflammation areas. Originally incorporated as Assertio Therapeutics, Inc., the company rebranded to Assertio Holdings, Inc. in May 2020. Assertio focuses on acquiring, developing, and commercializing differentiated pharmaceutical products. The company's portfolio includes several key medications, such as INDOCIN, used to treat moderate to severe rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and gouty arthritis. CAMBIA, another significant product, is a non-steroidal anti-inflammatory drug (NSAID) designed for the treatment of migraine, addressing symptoms such as nausea, photophobia, and phonophobia. Zipsor, also an NSAID, provides relief from mild to moderate acute pain. SPRIX is another NSAID used for short-term management of moderate to moderately severe pain requiring opioid-level analgesia. Otrexup, a single-dose auto-injector containing methotrexate, is prescribed for adults with severe, active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. Assertio's strategy involves acquiring and optimizing mature pharmaceutical products, leveraging its commercial expertise to enhance their market performance. The company competes with both branded and generic pharmaceutical manufacturers, emphasizing product differentiation and targeted marketing to maintain its position in the market. Assertio's approach combines strategic acquisitions with efficient commercial operations to deliver value in the specialty pharmaceutical sector.

What Products and Services Does ASRT Offer?

• Develops and commercializes specialty pharmaceutical products.
• Focuses on medications in neurology, hospital, and pain and inflammation areas.
• Markets INDOCIN for the treatment of rheumatoid arthritis and related conditions.
• Provides CAMBIA for migraine treatment.
• Offers Zipsor for relief of mild to moderate acute pain.
• Distributes SPRIX for short-term management of moderate to moderately severe pain.
• Sells Otrexup for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis.

How Does ASRT Make Money?

• Acquires and revitalizes mature pharmaceutical products.
• Focuses on niche markets and targeted therapies.
• Generates revenue through product sales and distribution.
• Employs a commercial infrastructure to market and sell its products.

What Industry Does ASRT Operate In?

Assertio Holdings, Inc. operates within the specialty pharmaceutical industry, a segment characterized by targeted therapies and niche markets. The industry is driven by innovation, regulatory approvals, and strategic acquisitions. Competition is intense, with companies vying for market share through product differentiation and pricing strategies. The market is influenced by factors such as patent expirations, generic drug penetration, and healthcare reforms. Assertio's focus on mature products positions it to capitalize on established markets while navigating the challenges of competition and regulatory oversight. The global pharmaceuticals market is projected to reach $1.7 trillion by 2027, growing at a CAGR of 5-8%.

Who Are ASRT's Key Customers?

• Patients suffering from rheumatoid arthritis, migraines, and acute pain.
• Hospitals and healthcare providers.
• Pharmacies and distributors.
• Adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis.

Company Profile

Assertio Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Lake Forest, US. The company is led by CEO Mark L. Reisenauer. ASRT has traded publicly since 1997.

ROE -39%Key Financial Metrics

Return on equity for Assertio Holdings, Inc. stands at -38.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -23.7%, the inverse of the P/E and a quick read on earnings relative to price.

ASRT Valuation & Market Position

With a $151.86M market cap, Assertio Holdings, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ASRT's quantitative score of 50/100 is below the peer average of 63/100.

Quarterly Financial Performance: Assertio Holdings, Inc.

Revenue for Assertio Holdings, Inc. came in at $9.9M during Q1 2026, a 26.7% contraction versus the preceding quarter. The company recorded a net loss of $18.9M, with diluted EPS of $-2.93. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, ASRT averaged $-1.42 in diluted EPS.

F-Score 2/9Financial Health

Assertio Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.71 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Assertio Holdings, Inc. revenue of about $105.9M for fiscal 2026, with EPS near $-1.69.

ASRT Financials

ASRT Latest News

ASRT Analyst Consensus

ASRT MoonshotScore

Latest Assertio Holdings, Inc. Analysis

ASRT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources